Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVe-AHEAD
NCT04939428Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Primary completion
- Nov 2022
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 23
01
Overview
A Phase 3 trial of molnupiravir in coronavirus disease 2019 (COVID-19), sponsored by Merck & Co.. Started Aug 2021; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04939428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939428.